Savara Inc (NASDAQ:SVRA) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its holdings in shares of Savara Inc (NASDAQ:SVRA) by 3.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,661 shares of the company’s stock after purchasing an additional 5,450 shares during the period. Dimensional Fund Advisors LP owned 0.08% of Savara worth $441,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Altium Capital Management LLC boosted its stake in Savara by 0.3% during the 4th quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company’s stock worth $4,848,000 after purchasing an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after buying an additional 4,732 shares during the last quarter. Barclays PLC raised its position in Savara by 2.5% during the 4th quarter. Barclays PLC now owns 236,705 shares of the company’s stock worth $728,000 after buying an additional 5,700 shares during the last quarter. SG Americas Securities LLC raised its position in Savara by 14.0% during the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after buying an additional 6,330 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Savara by 6.8% during the 4th quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock worth $434,000 after buying an additional 9,041 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

Shares of SVRA opened at $3.07 on Friday. The company has a 50-day simple moving average of $2.94 and a 200-day simple moving average of $3.03. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $530.34 million, a PE ratio of -7.14 and a beta of 0.44. Savara Inc has a 52-week low of $2.26 and a 52-week high of $5.11.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). Equities research analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Savara in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.